Phase II trial of aclacinomycin in acute leukemia and lymphosarcoma.
D015250:Aclarubicin / Q000031:analogs & derivatives*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009279:Naphthacenes / Q000627:therapeutic use*
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; C011157:aclacinomycins; D015250:Aclarubicin